Premedication Strategy for Weekly Paclitaxel

REFERENCES

• Rowinsky E.K., Onetto N., Canetta R.M., Arbuck G. Taxol: The First of the Taxanes, An Important New Class of Antitumor Agents. Semin. Oncol. 1992; 19: 646–662
   PubMed Web of Science ®Google Scholar
• Ozols R.F. The Fox Chase Cancer Center Investigators' Workshop and Consensus Conference. Semin. Oncol. 1999; 26(Suppl. 18)1–63
   Google Scholar
• Akerly W., Sikov W.M., Cummings F., Safran H., Strenger R., Marchant D. Weekly High-Dose Paclitaxel in Metastatic and Locally Advanced Breast Cancer: A Preliminary Report. Semin. Oncol. 1997; 24(Suppl. 17)87–90
   Google Scholar
• Chang A.Y., Boros L., Asbury R., Hui L., Rubin J. Dose-Escalation Study of Weekly 1-hour Paclitaxel Administration in Patients with Refractory Cancers. Semin. Oncol. 1997; 24(Suppl. 17)69–71
   Google Scholar
• CALGB 9840: A phase III trial of paclitaxel with trastuzumab in metastatic breast cancer. Cancer and Leukemia Group B, 1998.
   Google Scholar
• Choy H., Browne M.J. Paclitaxel as a Radiation Sensitizer in Non-Small Cell Lung Cancer. J. Clin. Oncol. 1994; 12: 2682–2686
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Safran H., et al. Multiinstitutional Phase II Trial of Paclitaxel, Carboplatin, and Concurrent Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. J. Clin. Oncol. 1998; 16: 3316–3322
   PubMed Web of Science ®Google Scholar
• Lau D.H.M., Ryu J., Gandara D., Morgan R., Doroshow J., Wilder R., Leigh B. Concurrent Twice-Weekly Paclitaxel and Thoracic Irradiation for Stage III Non-Small Cell Lung Cancer. Semin. Rad. Oncol. 1999; 9(Suppl. 1)117–120
   PubMedGoogle Scholar
• Lau D., Edelman M., Gandara D., et al. Concurrent Twice-Weekly Paclitaxel, Weekly Carboplatin and Radiation for Stage III Non-Small Cell Lung Cancer: A Phase II California Cancer Consortium Trial. Proc. Am. Soc. Clin. Oncol. 2000, Abstract
   PubMed Web of Science ®Google Scholar
• Lau D.H., Young L.J., Xue L., Burke P.A., Cheung A.T. Paclitaxel (Taxol): An Angiogenesis Inhibitor in a Highly Vascularized Transgenic Breast Cancer. Cancer Biother. Radiopharm. 1999; 14: 31–36
   PubMed Web of Science ®Google Scholar
• ECOG 1199: A phase III study of doxorubicin/cyclophosphamide therapy followed by paclitaxel or docetaxel given weekly or every 3 weeks in patients with axillary node-positive breast cancer. Eastern Cooperative Oncology Group, 1999.
   Google Scholar
• Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R., Van Echo D.A. Hypersensitivity Reaction from Taxol. J. Clin. Oncol. 1990; 7: 1263–1268
   Google Scholar
• Olson J.K., Sood A.K., Srosky J.I., Anderson B., Buller R.E. Taxol Hypersensitivity: Rapid Retreatment is Safe and Cost Effective. Gynecol. Oncol. 1998; 68: 25–28
   PubMed Web of Science ®Google Scholar
• Bookman M.A., Kloth D.D., Kover P.E., Smolinski S., Ozols R.F. Intravenous Prophylaxis for Paclitaxel-Related Hypersensitivity Reactions. Semin. Oncol. 1997; 69(Suppl. 19)13–15
   Google Scholar
• Arbuck S.G., Christian M.C., Fisherman J.S., Cazebave A., Sarosy G., Suffness M. Clinical Development of Taxol. Monogr. J. Natl Cancer Inst. 1993; 15: 11–24
   PubMedGoogle Scholar
• Reckzeh B., Merte H., Pfluger K.H., Pfab R., Wolf M., Havemann K. Severe Lymphocytopenia and Interstitial Pneumonia in Patients Treated with Paclitaxel and Simultaneous Radiotherapy for Non-Small-Cell Lung Cancer. J. Clin. Oncol. 1996; 14: 1071–1076
   PubMed Web of Science ®Google Scholar
• Peereboom D.M., Donehower R.C., Eisenhauer E.A., McGuire W., Onetto N., Hubbard J.L., Piccart M., Rowinsky E.K. Successful Re-treatment with Taxol After Major Hypersensitivity Reactions. J. Clin. Oncol. 1993; 5: 885–890
   Google Scholar
• Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. J. Clin. Oncol. 2000; 18: 102–105
   PubMed Web of Science ®Google Scholar
• Quock J., Dea G., Lim N., Tanaka M., Gandara D., Lau D. Premedication Strategy for Weekly Paclitaxel Based on Experience with 1608 Infusions of 3- and 4-Week Paclitaxel. Proc. Am. Soc. Clin. Oncol. 1999; 18: 165, Abstract
   Google Scholar
• Lau D., Leigh B., Gandara D., et al. Twice Weekly Paclitaxel and Weekly Carboplatin with Concurrent Thoracic Radiation followed by Carboplatin/Paclitaxel Consolidation for Stage III Non-small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial. J. Clin. Oncol. 2001; 19: 442–447
   PubMed Web of Science ®Google Scholar